Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

In a pilot study, two doses of neoadjuvant nivolumab administered to patients with resectable lung cancer resulted in a major pathological response in 45% and amplified T-cell clones specific for tumor antigens.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2018-05, Vol.378 (21), p.1976-1986
Hauptverfasser:	Forde, Patrick M, Chaft, Jamie E, Smith, Kellie N, Anagnostou, Valsamo, Cottrell, Tricia R, Hellmann, Matthew D, Zahurak, Marianna, Yang, Stephen C, Jones, David R, Broderick, Stephen, Battafarano, Richard J, Velez, Moises J, Rekhtman, Natasha, Olah, Zachary, Naidoo, Jarushka, Marrone, Kristen A, Verde, Franco, Guo, Haidan, Zhang, Jiajia, Caushi, Justina X, Chan, Hok Yee, Sidhom, John-William, Scharpf, Robert B, White, James, Gabrielson, Edward, Wang, Hao, Rosner, Gary L, Rusch, Valerie, Wolchok, Jedd D, Merghoub, Taha, Taube, Janis M, Velculescu, Victor E, Topalian, Suzanne L, Brahmer, Julie R, Pardoll, Drew M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - pathology Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antigens Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Apoptosis B7-H1 Antigen - antagonists & inhibitors Biopsy Body weight Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - surgery Carcinoma, Squamous Cell - pathology Chemotherapy Cloning Drug dosages Feasibility studies Female Gene expression Humans Immunotherapy Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Lung Neoplasms - surgery Lymphatic system Lymphocytes Lymphocytes T Male Middle Aged Monoclonal antibodies Mutation Neoadjuvant Therapy Neoantigens Nivolumab Non-small cell lung carcinoma Patients PD-1 protein PD-L1 protein Peptides Peripheral blood Pilot Projects Side effects Surgery T cell receptors Targeted cancer therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a pilot study, two doses of neoadjuvant nivolumab administered to patients with resectable lung cancer resulted in a major pathological response in 45% and amplified T-cell clones specific for tumor antigens.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1716078